One of the biggest challenges in oncology is the development of drug resistance, where tumor cells eventually "learn" to pump out toxins or stop expressing the target antigen. However, new research featured in the Antibody Drug Conjugate Market analysis suggests that newer ADCs are being designed with a "bystander effect." This allows the drug to kill neighboring cancer cells even if they don't possess the specific target marker, effectively neutralizing tumor heterogeneity.

Within the US Antibody Drug Conjugate Market, clinical trials are increasingly focusing on dual-payload ADCs. These "cocktail" conjugates deliver two different types of drugs at once—such as a microtubule inhibitor and a DNA-damaging agent—making it significantly harder for the cancer to evolve resistance. As these move through FDA approval, they are expected to become the new standard for refractory cases.